Compare
Sunshine Biopharma Inc. vs Lftd Partners Inc. vs Earth Science Tech, Inc. vs Verrica Pharmaceuticals Inc.
| Latest fiscal year | Sunshine Biopharma Inc. SBFM | Lftd Partners Inc. LIFD | Earth Science Tech, Inc. ETST | Verrica Pharmaceuticals Inc. VRCA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-03-31 | 2025-12-31 |
| Revenue | $36.31M | $36.92M | $35.70M | $35.58M |
| Revenue growth (YoY) | +4.1% | -1.1% | +7.8% | +370.2% |
| Gross margin | 33.8% | 34.2% | 71.4% | n/a |
| Operating margin | -17.2% | 2.5% | n/a | -34.2% |
| Net margin | -16.5% | -67.3% | 10.2% | -50.3% |
| Net income | -$5.98M | -$24.86M | $3.63M | -$17.89M |
| EPS (Diluted) | n/a | -$1.68 | $0.012 | -$1.68 |
| Operating cash flow | -$5.33M | $1.32M | $1.94M | -$17.63M |
| Free cash flow | -$5.51M | $1.20M | $1.18M | -$17.63M |
| Cash & equivalents | n/a | $1.77M | $796.8K | $30.15M |
| Total assets | $30.08M | $19.27M | $8.97M | $47.13M |
| Total liabilities | $7.04M | $6.64M | $1.93M | $22.39M |
| Shareholders' equity | $23.04M | $12.63M | $7.01M | $24.74M |
| Return on year-end equity | -25.9% | -196.8% | 51.8% | -72.3% |
| Shares outstanding | 4.91M | 14.82M | 291.32M | 17.18M |
Revenue, most recent five fiscal years
| Fiscal year | Sunshine Biopharma Inc. | Lftd Partners Inc. | Earth Science Tech, Inc. | Verrica Pharmaceuticals Inc. |
|---|---|---|---|---|
| Latest | $36.31M Ended 2025-12-31 | $36.92M Ended 2025-12-31 | $35.70M Ended 2026-03-31 | $35.58M Ended 2025-12-31 |
| 1 year earlier | $34.87M Ended 2024-12-31 | $37.33M Ended 2024-12-31 | $33.12M Ended 2025-03-31 | $7.57M Ended 2024-12-31 |
| 2 years earlier | $24.09M Ended 2023-12-31 | $51.61M Ended 2023-12-31 | $11.95M Ended 2024-03-31 | $5.12M Ended 2023-12-31 |
| 3 years earlier | $4.35M Ended 2022-12-31 | $57.42M Ended 2022-12-31 | $48.5K Ended 2023-03-31 | $9.03M Ended 2022-12-31 |
| 4 years earlier | $228.4K Ended 2021-12-31 | $31.66M Ended 2021-12-31 | $14.1K Ended 2022-03-31 | $12.00M Ended 2021-12-31 |